(Q36835807)

16 August 2017

1 reference

title

Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

Tim R Cressey

1

1 reference

16 August 2017

Nottasorn Plipat

series ordinal

2

1 reference

16 August 2017

Federica Fregonese

series ordinal

3

1 reference

16 August 2017

Kulkanya Chokephaibulkit

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

347-361

1 reference

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetic profile and tolerability of indinavir-ritonavir combinations in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

A phase I/II study of the protease inhibitor indinavir in children with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

The binding of HIV-1 protease inhibitors to human serum proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Interactions among drugs for HIV and opportunistic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir and rifabutin drug interactions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir concentrations and St John's wort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics of indinavir in Koreans and Caucasians.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

The use of antiretroviral agents in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir crystallization around the loop of Henle: experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Crystalluria and urinary tract abnormalities associated with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Incidence and risk factors for the development of indinavir-associated renal complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the ATHENA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Long-Term Efficacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease Inhibitor--Naive Adults with Advanced HIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Renal atrophy associated with long-term treatment with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Papillary necrosis associated with the HIV protease inhibitor indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Mechanism of indinavir-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir-associated lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Hypertrophy of the breasts in a patient treated with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Metabolic effects of indinavir in healthy HIV-seronegative men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Indinavir-induced retinoid-like effects: incidence, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

HIV-protease inhibitors alter retinoic acid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Protease inhibitor therapy in children with perinatally acquired HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Symptomatic hyperbilirubinemia with indinavir/ritonavir-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.347

21 January 2018

Identifiers

DOI

10.1517/17425255.3.3.347

1 reference

16 August 2017

1 reference